CPIXMEDIUM SIGNALOPERATIONAL10-K

Cumberland Pharmaceuticals completed its Phase II DMD study and initiated FDA interactions while demonstrating improved operational performance with reduced losses and revenue growth.

The company has progressed its ifetroban DMD program from data collection to regulatory engagement, representing a meaningful advancement in its pipeline development. The shift from "Phase II study" language to "breakthrough results" and "clinical study report" submission indicates the company is moving closer to potential commercialization discussions with the FDA.

Comparing 2026-03-09 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

Cumberland showed meaningful operational improvement with losses substantially reduced while revenue grew 16.7% to $42.0M. The company's working capital expanded with notably higher inventory and accounts receivable, though cash declined significantly by $6.6M to $11.4M. The combination of reduced losses, revenue growth, and increased working capital suggests business expansion, though the cash decrease warrants monitoring for liquidity management.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+56.6%
-$6.4M→-$2.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+56.2%
-$6.5M→-$2.8M

Net income grew 56.2% — bottom-line growth signals improving overall business health.

Inventory
Balance Sheet
+55.6%
$4.0M→$6.2M

Inventory surged 55.6% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Share Buybacks
Cash Flow
-54.5%
$579K→$263K

Buyback activity reduced 54.5% — capital being redeployed elsewhere or cash conservation underway.

Capital Expenditure
Cash Flow
+47.3%
$66K→$98K

Capital expenditure jumped 47.3% — major investment cycle underway; assess returns on deployment.

Accounts Receivable
Balance Sheet
+44.8%
$11.7M→$16.9M

Receivables surged 44.8% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Cash & Equivalents
Balance Sheet
-36.3%
$18.0M→$11.4M

Cash declined 36.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Revenue
P&L
+16.7%
$36.0M→$42.0M

Revenue growing 16.7% — solid top-line momentum, watch margins for quality of growth.

Current Liabilities
Balance Sheet
+16.2%
$31.6M→$36.7M

Current liabilities rose 16.2% — increased short-term obligations, watch current ratio.

R&D Expense
P&L
+15.6%
$4.8M→$5.6M

R&D investment increased 15.6% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-07
ADDED
The aggregate market value of common stock held by non-affiliates as of June 30, 2025 was $ 29,403,593 .
AND SUBSIDIARIES Index Page Number PART I 1 Item 1: Business 1 Item 1A: Risk Factors 36 Item 1B: Unresolved Staff Comments 62 Item 1C.
In addition to these commercial brands, we have announced breakthrough results in a clinical study of our ifetroban product candidate in patients with cardiomyopathy associated with Duchenne muscular dystrophy ( DMD ).
This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles.
We then completed and submitted a clinical study report to the FDA and began interactions to determine their remaining development requirements.
Cumberland has built core competencies for the acquisition, development, registration and commercialization of pharmaceutical products in the U.S.
1 Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion arrangements.
Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability and delivery of our products, both domestically and internationally.
Our 2025 sustainability metrics noted that during that year we provided nearly 5 million patient doses of our brands, while safely disposing of over 5,500 pounds of expired and damaged goods.
We reported women represented 50% of Cumberland s workforce and 30% of our employees were minorities.
REMOVED
The aggregate market value of common stock held by non-affiliates as of June 30, 2024 was $ 12,234,822 .
AND SUBSIDIARIES Index Page Number PART I 1 Item 1: Business 1 Item 1A: Risk Factors 34 Item 1B: Unresolved Staff Comments 57 Item 1C.
Additionally, we recently completed a Phase II study in patients with cardiomyopathy associated with Duchenne muscular dystrophy ( DMD ), a rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles.
Next steps for this DMD Program include further data analysis and completion of a full study report in preparation for an end-of-Phase-II meeting with the FDA to determine next steps associated with the product s development and commercialization.
Cumberland has built core competencies for the acquisition, development and commercialization of pharmaceutical products in the U.S.
Our business development team identifies, evaluates, and negotiates product acquisition, licensing and co-promotion agreements.
Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability and delivery of our products.
Our 2024 sustainability metrics noted that during that year we provided 3.9 million patient doses of our brands, while safely disposing of nearly 12,480 pounds of expired and damaged goods.
We reported that women represented 49% of Cumberland s workforce and 27% of our employees were minorities.
These filings are also available to the public at www.sec.gov.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →